Adenosine deaminase Inhibitors
2 drugsAbout Adenosine deaminase
Adenosine deaminase (ADA) is an enzyme that catalyzes the irreversible deamination of adenosine to inosine, crucial for purine metabolism and cellular function.
While there is currently no genetic evidence directly linking ADA to specific diseases, two FDA-approved drugs, NELARABINE and REVCOVI, underscore its therapeutic potential.
ADA is targeted by two FDA-approved drugs: NELARABINE (small molecule) and REVCOVI (biologic other), developed by XGEN PHARMS and CHIESI USA INC, respectively.
Top Adenosine deaminase Drugs
The competitive landscape consists of two companies, XGEN PHARMS and CHIESI USA INC, with approved drugs.
Low market concentration suggests opportunities for new entrants to gain market share.
Adenosine deaminase Drug Modality Landscape
Modalities
Routes of Administration
Adenosine deaminase is druggable by both biologics (1) and small molecules (1), indicating broad therapeutic accessibility.
Explore opportunities to develop novel modalities beyond small molecules and biologics.
📈 Modality Evolution
other biologics pioneered Adenosine deaminase targeting (2018), with small molecules entering more recently (2021).
Adenosine deaminase Clinical Trials 14 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Adenosine deaminase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 2 | 2 | 1 | 50% |
| Phase 2 | 6 | 0 | 3 | 3 | 0% |
| Phase 3 | 3 | 1 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Adenosine deaminase Drug Approval Timeline (2018 - 2021)
The first drug was approved in 2018, with the most recent approval in 2021, spanning 4 years.
Recent approvals indicate continued interest, but further approvals may saturate the market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 11 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Adenosine deaminase. A trial counts if an approved drug acting on Adenosine deaminase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.